Christopher Ung

Scientific Business Chief & Officer CellCarta Inc

Tuesday 6th October 2026

Chair’s Opening Afternoon Remarks

2:00 pm

Wednesday 7th October 2026

Panel Discussion: Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment

11:20 am

One Frontier Model, For Every Stage of Drug Development: Discover how a unified ecosystem powered by a single frontier AI model streamlines biomarker discovery, clinical trial stratification, regulatory-grade diagnostics, and global deployment to pathology labs. Platform agnostic development under one roof – no need for algorithm hand-offs or tedious integrations before deployment
De-Risking CDx Timelines With Tissue AI: AI-driven biomarker signal detection reduces trial enrollment risk and enables more informed decisions from less tissue — shortening Rx-Dx co-development time
Redefining Global Pathology Routine: Moving tissue biomarkers from isolated reference labs to global clinical routine powered by our extensive CRO partnerships and an active lab network

Wednesday 7th October 2026

The CDx Model Needs to Change – What China Taught Us About Breaking Silos, Moving Faster, & Going Global

12:10 pm

Where the traditional model creates friction for biopharma teams
How we developed a model based on: Early alignment, multiplayer integration and communication
Phase 3 trial implementation: After model validation in China, we're scaling globally to support teams across CDx development stages

Thursday 8th October 2026

Can AI Predict ADC Response?

11:00 am